The patent covers combination therapy for modifying glucose metabolism comprising administration of a dipeptidyl peptidase IV (DPIV) inhibitor and a further therapeutic agent, such as metformin.
OSI has an exclusive sub-licensable license under the US patent and corresponding equivalents worldwide for the use of non-boronic acid DPIV inhibitors through its Prosidion subsidiary.
The company acquired its DPIV technology platform from Probiodrug AG in June 2004. In addition to a phase II compound, PSN9301, the platform comprises a portfolio of DPIV medical use patents. These include issued patents and pending patent applications with claims covering DPIV as a target for anti-diabetes therapy and the use of combinations of DPIV inhibitors with other anti-diabetic drugs.
“Inhibition of DPIV is one of the most promising new strategies for the treatment of type 2 diabetes and combination therapy could represent a significant component of the market for DPIV inhibitors,” stated Dr Anker Lundemose, president of (OSI) Prosidion. “The grant of this patent strengthens the portfolio of DPIV assets acquired by Prosidion last year.”